newsfilter
← Latest News
GlobeNewswire·

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

  • Kymera Therapeutics will report Phase 1 results for KT-579 in healthy volunteers on Thursday, October 29, 2026.
  • The findings cover single & multiple-ascending doses of KT-579 & will be shared during the company's third quarter 2026 financial results.
  • A video conference call & webcast is scheduled for 8:30 a.m. ET on the release date.
  • KT-579 is an investigational, first-in-class, oral degrader targeting IRF5, a master regulator of immunity.
  • The drug aims to modulate multiple core inflammatory pathways to treat autoimmune diseases such as lupus, Sjögren's, rheumatoid arthritis, & inflammatory bowel disease.
  • Kymera Therapeutics is a clinical-stage biotechnology firm founded in 2016 that pioneers targeted protein degradation for immunological diseases.